Search results
Medimmune Math Adds Up to Higher Value Justin Ferayorni The company's labeled as overvalued, but its two franchises and strong pipeline bode well for the shares.
'The IL-5 receptor program is an excellent strategic fit for MedImmune as we continue to expand our research and development pipeline with promising targets that are consistent with our areas of therapeutic focus and scientific expertise,' said Barbara White, M.D., MedImmune's senior director, clinical development, inflammatory disease.
MedImmune Heats Up By MOHAMMED HADI February 16, 2007; [WSJ] Page C7 Driven by one part good news and one part wishful thinking, trading in shares and call options of drug developer MedImmune Inc. was heavy yesterday. Shares of the Gaithersburg, Md., company jumped $1.91, or 6.1%, to $33.16 on th...
Medimmune (MEDI) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.
Feb 14, 2019 · Yet several MedImmune-developed drugs will be key to AstraZeneca’s return to growth, including the PD-L1 inhibitor Imfinzi (durvalumab) and the asthma therapy Fasenra (benralizumab). AstraZeneca recorded $633 million in Imfinzi sales for 2018, and now expects peak U.S. sales of at least $1 billion. Fasenra, meanwhile, fetched $297 million ...
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.
People also ask
Where is MedImmune based?
Why did AstraZeneca retire MedImmune?
When did MedImmune buy FluMist?
Apr 3, 2013 · AstraZeneca announced that MedImmune, its global biologics research and development unit, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the ...
